NCT03821792View on ClinicalTrials.gov

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

October 11, 2026

Study Completion Date

October 11, 2026

Conditions

Metastatic Prostate CarcinomaProstate AdenocarcinomaProstate Carcinoma Metastatic in the BoneStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8

Interventions

DRUG

Abiraterone Acetate

Given PO

DRUG

Apalutamide

Given PO

DRUG

Prednisone

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER